Bayesian, AUC-guided vancomycin dosing — free for clinicians.
Start with an empiric regimen built from your patient’s characteristics, then refine it with one or two measured levels. Targets follow the 2020 ASHP/IDSA/PIDS/SIDP consensus guideline, and the model, assumptions and limitations are shown with every result.
From the first dose to level-guided adjustment.
Clinical decision support for adults receiving intermittent intravenous vancomycin, built on published models and guideline targets.
- 01
AUC₂₄-guided targets
Suggested regimens aim for an AUC₂₄ of 400–600 mg·h/L, the target range recommended for serious MRSA infections (assuming an MIC of 1 mg/L) by the 2020 ASHP/IDSA/PIDS/SIDP vancomycin consensus guideline.
Rybak MJ et al. Am J Health Syst Pharm. 2020;77(11):835-864. - 02
Empiric dosing from patient characteristics
Before any levels are available, get a suggested starting regimen, including loading-dose guidance, based on age, weight, serum creatinine and other patient characteristics.
- 03
Refinement with one or two levels
Enter one or two measured vancomycin levels and the estimate is individualized to your patient with Bayesian methods. The adjustment is bounded, so one unusual level cannot override the population data.
- 04
Colin 2019 pooled population model
A published, peer-reviewed analysis that pools 14 vancomycin studies. Vancomyzer shows the model, assumptions and evidence behind each estimate.
Colin PJ, et al. Vancomycin pharmacokinetics throughout life: results from a pooled population analysis and evaluation of current dosing recommendations. Clin Pharmacokinet. 2019;58(6):767-780. - 05
One model for all adults, with a high-BMI advisory
Colin 2019 is used throughout the supported adult workflow. At a BMI of 40 kg/m² or higher, an advisory notes that published evaluation at that size is limited, and fat-free mass and alternative creatinine-clearance estimates are shown for context only. They do not change the calculation.
Colin PJ, et al. Ther Drug Monit. 2021;43(1):126-130. PMID: 33278242. - 06
Built-in safety checks
Infusions are kept to a maximum rate of 10 mg/min and at least 60 minutes. Recommendations are withheld for dialysis or renal replacement therapy, and warnings flag severely reduced kidney function, questionable level timing and a poor fit to measured levels.
Review the evidence before you rely on it.
Every model, equation and published source is documented. Vancomyzer has not yet been validated in real patients. Its equations are checked against published values and synthetic test cases; external validation with patient data is planned. The results of those developer-run checks are public.
- Transparent DosingOur approach in plain terms: the models, the published sources behind them, and what the calculator will not do.
- Equations & DerivationsThe full equations behind every calculation, each with its primary citation.
- Literature ReproducibilityPublished vancomycin cases run through the calculator. Same-model Colin 2019 reproductions are pass/fail; cases from other published models are shown for context only.
- Predictive PerformanceA developer-run synthetic analysis (not real patients): predictions compared with simulated ICU patients generated from a different published model.
- Engine Cross-CheckA developer-run synthetic analysis (not real patients): our individualized estimates compared with Tucuxi, a separately built dosing program given the same priors, scored against pre-set acceptance criteria.
- Frequently Asked QuestionsInputs, methods, limitations and common clinical questions.
Built for the clinicians who dose and monitor vancomycin.
- Pharmacists
- Physicians
- Nurse practitioners
- Physician assistants
- Residents
- Students
Intended for qualified healthcare professionals and clinical trainees. Every recommendation must be independently reviewed by a licensed clinician before any change to therapy. Not intended for patients or caregivers.
Know where it applies.
- Pediatric patients
- Patients on dialysis or other renal replacement therapy
- Continuous-infusion vancomycin
Vancomyzer™ is designed to meet the criteria for non-device clinical decision support in section 520(o)(1)(E) of the Federal Food, Drug, and Cosmetic Act (added by section 3060 of the 21st Century Cures Act). It has not been cleared, approved or otherwise reviewed by the FDA. It is intended for licensed healthcare professionals, who must independently review the basis for each recommendation. It supports, and does not replace, clinical judgment: review every recommendation against the patient’s clinical status, institutional protocols and therapeutic drug monitoring before any change to therapy.
Read the full medical disclaimer →Open the calculator.
The core calculator is free, permanently. During our launch period, PDF export, note copy and result interpretation are free too — no account needed.